標(biāo)題: Titlebook: Discovering and Developing Molecules with Optimal Drug-Like Properties; Allen C Templeton,Stephen R. Byrn,Thomas E. Prisin Book 2015 Ameri [打印本頁] 作者: 他剪短 時間: 2025-3-21 19:53
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties影響因子(影響力)
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties影響因子(影響力)學(xué)科排名
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties網(wǎng)絡(luò)公開度
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties被引頻次
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties被引頻次學(xué)科排名
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties年度引用
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties年度引用學(xué)科排名
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties讀者反饋
書目名稱Discovering and Developing Molecules with Optimal Drug-Like Properties讀者反饋學(xué)科排名
作者: Conducive 時間: 2025-3-21 21:03 作者: 表被動 時間: 2025-3-22 02:24
Enabling Discovery Through Leveraging and Miniaturizing Pharmaceutical Principles and Processesneed to execute in a parallel fashion. These realities in turn can place severe restrictions on the options available to the development and implementation of drug delivery strategies. While one would expect the contrary, these realities do not preclude the use of development-stage formulation techn作者: 的闡明 時間: 2025-3-22 08:13
Diagnosing Biopharmaceutical Limitationsands adequate exposure throughout the dosing interval and none of the compounds tested approaches the targeted exposure. Studying compounds to determine why exposure is poor may assist the structure–activity relationship (SAR) process, even if the compounds are not suitable for further development. 作者: 空氣 時間: 2025-3-22 12:23 作者: 腐蝕 時間: 2025-3-22 16:38 作者: 腐蝕 時間: 2025-3-22 18:55 作者: 狂熱文化 時間: 2025-3-22 23:23 作者: Platelet 時間: 2025-3-23 01:26 作者: 輕觸 時間: 2025-3-23 07:39
Practical Considerations for Spray Dried Formulation and Process Developmentug to a high energy polymer stabilized amorphous state. Spray drying is a mature process with demonstrated production capability from lab to commercial scale for manufacturing amorphous solid dispersions. However, the impact of the drying process on the performance, manufacture, and stability of the作者: TEN 時間: 2025-3-23 13:32 作者: 短程旅游 時間: 2025-3-23 16:34
Leveraging Solid State Form and Physiochemical Properties for Early Clinical Formulation Efforts: Opm, which can be either a liquid or a semisolid, is typically filled into hard-shell or soft gelatin capsules. Due to the relatively straightforward formulation development steps required, LBFs are especially suitable to support early phase clinical studies for a new chemical entity. However, line-of作者: 防止 時間: 2025-3-23 19:24
Christian Mangold,Gerrit Seidelin combination, can be applied prior to candidate selection. Such approaches include in silico predictions, surrogate measurements mimicking biorelevant conditions, learnings from related compounds and rapid screening of multiple solid forms, formulation and delivery technologies. In the end, a cros作者: Myofibrils 時間: 2025-3-24 01:29 作者: 冷漠 時間: 2025-3-24 04:35 作者: 騙子 時間: 2025-3-24 06:54
https://doi.org/10.1007/978-3-658-17634-1s can also be used to obtain a fundamental understanding of the system and be predictive of changes across process spaces. The properties of spray dried powder are amenable to multiple drug delivery routes such as oral suspensions and solid oral dosage forms. However, the process and environmental s作者: insecticide 時間: 2025-3-24 13:19
Wolfram Jost,August-Wilhelm Scheerubility in the excipient matrix, capsule cross-linking, as well as physical and chemical instability. Initially, telcagepant was formulated as a liquid LBF using the crystalline neutral form of the molecule, aided by in situ salt formation, and filled into hard-shell gelatin capsules. Following an e作者: filicide 時間: 2025-3-24 18:07
2210-7371 opertiesand critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on lin978-1-4939-4860-4978-1-4939-1399-2Series ISSN 2210-7371 Series E-ISSN 2210-738X 作者: 不近人情 時間: 2025-3-24 20:15 作者: 行乞 時間: 2025-3-25 00:40
Discovery Formulations: Approaches and Practices in Early Preclinical Development suboptimal biopharmaceutical properties, dose, compound purity, compound availability, and aggressive timelines. This chapter will cover formulations used in the discovery setting from conventional vehicles to solubilizing systems and alternate delivery approaches. The application of the appropriat作者: 繁榮中國 時間: 2025-3-25 03:47
Performance and Characterization of Amorphous Solid Dispersions: An Overviewng drug absorption and the use of dimensionless numbers and absorption modeling in formulation selection. We provide an in-depth description of the concepts of supersaturation, crystallization, and speciation during dissolution, and their effect on product performance. Finally, solid-state failure m作者: ARM 時間: 2025-3-25 11:24
Practical Considerations for Spray Dried Formulation and Process Developments can also be used to obtain a fundamental understanding of the system and be predictive of changes across process spaces. The properties of spray dried powder are amenable to multiple drug delivery routes such as oral suspensions and solid oral dosage forms. However, the process and environmental s作者: Antagonism 時間: 2025-3-25 15:15
Leveraging Solid State Form and Physiochemical Properties for Early Clinical Formulation Efforts: Opubility in the excipient matrix, capsule cross-linking, as well as physical and chemical instability. Initially, telcagepant was formulated as a liquid LBF using the crystalline neutral form of the molecule, aided by in situ salt formation, and filled into hard-shell gelatin capsules. Following an e作者: FECK 時間: 2025-3-25 19:00
Book 2015d discovery and early development candidates, highlighting the link between solid state propertiesand critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on lin作者: nurture 時間: 2025-3-25 23:51 作者: 脆弱吧 時間: 2025-3-26 03:35
,Die ?Samstags geh?rt Vati mir“-Kampagne,o-end” formulation approaches for poorly soluble compounds, i.e., nanosizing or nanonization. The approach is broadly applicable for parenteral and non-parenteral dosage forms and has been commercially validated with the launch of products such as Rapamune., Emend., TriCor. 145, Triglide., Megace ES., Invega. Sustenna., Abraxane., and Juvedical..作者: 溺愛 時間: 2025-3-26 06:09 作者: Osteoarthritis 時間: 2025-3-26 11:24 作者: Obsequious 時間: 2025-3-26 14:02 作者: 善變 時間: 2025-3-26 20:50
https://doi.org/10.1007/978-3-322-87001-8mical properties of molecules through medicinal chemistry. Insights will be provided into the differences in approaches needed for optimization of a biological probe for target validation versus that of a hit to lead campaign, the design of more drug-like libraries, and the over-reliance of potency in optimization campaigns.作者: 殺蟲劑 時間: 2025-3-27 00:29 作者: bifurcate 時間: 2025-3-27 01:41 作者: Gourmet 時間: 2025-3-27 08:58 作者: parasite 時間: 2025-3-27 13:28 作者: amygdala 時間: 2025-3-27 15:49
Hot-Melt Extrusion: The Process-Product-Performance Interplaycan be leveraged to model the extrusion process when appropriate material properties are understood. The fundamental concepts provided herein will facilitate successful manufacture and scale-up of the extrusion process.作者: 愛國者 時間: 2025-3-27 21:32
2210-7371 hich a pharmacological benefit can be found.Examines the rea.This authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Writt作者: 有罪 時間: 2025-3-28 01:50 作者: Limpid 時間: 2025-3-28 05:41 作者: Generic-Drug 時間: 2025-3-28 08:32 作者: FLIP 時間: 2025-3-28 12:42
Allen C Templeton,Stephen R. Byrn,Thomas E. PrisinAddresses the challenge to more efficiently select better molecules for drug development.Discusses how to expand the chemical space within which a pharmacological benefit can be found.Examines the rea作者: GIDDY 時間: 2025-3-28 18:33 作者: AWL 時間: 2025-3-28 22:07
Discovering and Developing Molecules with Optimal Drug-Like Properties978-1-4939-1399-2Series ISSN 2210-7371 Series E-ISSN 2210-738X 作者: 發(fā)怨言 時間: 2025-3-29 02:08
Ulrike R?ttger,Volker Gehrau,Joachim Preussethe atomic level. Methods for screening the glass forming ability of drug–polymer mixtures under containerless conditions, constructing phase diagrams, and extracting bonding interactions between the drug and polymer molecules are outlined.作者: 擔(dān)心 時間: 2025-3-29 03:27
Andres Friedrichsmeier,Silke FürstThis chapter provides an overview of the concepts of quality and risk in early development. It utilizes the FDA quality by design wheel and emphasizes the concept of learning before doing. This chapter also emphasizes stability and factors that lead to instability. Finally, this chapter addresses moisture and moisture uptake.作者: FECT 時間: 2025-3-29 08:38 作者: insolence 時間: 2025-3-29 12:09 作者: encyclopedia 時間: 2025-3-29 18:28 作者: 十字架 時間: 2025-3-29 21:40
Advanced X-Ray Analytical Methods to Understand Structure, Properties, and Riskthe atomic level. Methods for screening the glass forming ability of drug–polymer mixtures under containerless conditions, constructing phase diagrams, and extracting bonding interactions between the drug and polymer molecules are outlined.作者: 開玩笑 時間: 2025-3-30 00:42
Christian Mangold,Gerrit Seideldevelopment path utilizing minimum resources, material and time. An early assessment of developability and associated risks during drug discovery can expedite the candidate selection process, enable developable candidates to move faster into clinic and weed out non-developable candidates sooner rath作者: FLAX 時間: 2025-3-30 07:59
Herbert Wanner,Mireille J. Quirinamaceutical industry. Given the complexity of modern drug discovery, this goal can only be achieved through well-designed pharmacology, pharmacokinetic, and toxicology studies resulting in the identification of exceptional development candidates. Pivotal to the success of these studies is the use of
